Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for primary cutaneous T-cell lymphoma has been reported in the published literature.
Estimated prevalence: 1-5 in 10,000 (Uncommon).
27 clinical trials registered, 16 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 8 PHASE2, 8 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05978141](https://clinicaltrials.gov/study/NCT05978141) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Registry for People With T-cell Lymphoma |
— |
Memorial Sloan Kettering Cancer Center |
RECRUITING |
[NCT05333367](https://clinicaltrials.gov/study/NCT05333367) | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy | NA | Centre Hospitalier Universitaire de Besancon | RECRUITING |
[NCT06698822](https://clinicaltrials.gov/study/NCT06698822) | A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA | PHASE2 | M.D. Anderson Cancer Center | RECRUITING |
[NCT07160023](https://clinicaltrials.gov/study/NCT07160023) | Local Registry of Primary Cutaneous T-cell Lymphomas | — | Fondazione IRCCS Policlinico San Matteo di Pavia | RECRUITING |
[NCT07356245](https://clinicaltrials.gov/study/NCT07356245) | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | PHASE2 | Jonathan Brammer | RECRUITING |
61 publications have been identified in PubMed for primary cutaneous T-cell lymphoma. Research spans Case Report / Case Series (39%), Epidemiology / Natural History (16%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 24 | 39% |
Disease patterns and progression | 10 | 16% |
Laboratory research | 8 | 13% |
Research summaries | 7 | 11% |
Clinical study results | 6 | 10% |
Testing and diagnosis research | 3 | 5% |
New treatment approaches | 2 | 3% |
Other research | 1 | 2% |
Zhao S (2026). [PMID: 41560049](https://pubmed.ncbi.nlm.nih.gov/41560049/). *Medicine*. [Case Report / Case Series]
Ramesh R (2026). [PMID: 41815286](https://pubmed.ncbi.nlm.nih.gov/41815286/). *Blood neoplasia*. [Basic Science / Preclinical]
Higgins MJ (2026). [PMID: 41271171](https://pubmed.ncbi.nlm.nih.gov/41271171/). *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. [Clinical Trial Publication]
Poligone B (2026). [PMID: 41920467](https://pubmed.ncbi.nlm.nih.gov/41920467/). *Oncol Ther*. [Clinical Trial Publication]
Mozas P (2026). [PMID: 42055866](https://pubmed.ncbi.nlm.nih.gov/42055866/). *Blood Rev*. [Review / Meta-Analysis]
Ratnayake P (2026). [PMID: 41962142](https://pubmed.ncbi.nlm.nih.gov/41962142/). *Am J Dermatopathol*. [Case Report / Case Series]
Xie R (2026). [PMID: 42116405](https://pubmed.ncbi.nlm.nih.gov/42116405/). *Medicine (Baltimore)*. [Diagnostic / Biomarker]
Varela A (2026). [PMID: 41970102](https://pubmed.ncbi.nlm.nih.gov/41970102/). *Cureus*. [Case Report / Case Series]
Linde P (2026). [PMID: 42183626](https://pubmed.ncbi.nlm.nih.gov/42183626/). *Acta Oncol*. [Epidemiology / Natural History]
Tran GH (2026). [PMID: 41105046](https://pubmed.ncbi.nlm.nih.gov/41105046/). *The American Journal of dermatopathology*. [Case Report / Case Series]
AI-curated news mentioning primary cutaneous T-cell lymphoma
Updated Jul 21, 2026
A 20-year study on primary cutaneous γδ T-cell lymphoma reveals significant clinical heterogeneity, providing insights into patient management and treatment strategies. This research underscores the complexity of this rare lymphoma subtype.
Recent studies highlight the potential of brentuximab vedotin in treating cutaneous T-cell lymphoma, particularly in CD30-negative and CD30-low cases. This emerging evidence could inform future therapeutic strategies for this challenging subset of the disease.
Ongoing clinical trials are exploring new therapies for cutaneous T-cell lymphoma, focusing on innovative strategies that do not rely on a patient's own T cells. Experts express optimism about the potential effectiveness of these early-phase trials in the coming years.
Researchers have developed and preliminarily validated the CTCL-PRO-20, a new quality of life survey specifically for patients with cutaneous T-cell lymphoma. This tool aims to enhance the understanding of patient experiences and outcomes in this rare disease.